Intro

This chapter explores the Rand Corporation's findings on the disparity of drug prices in the US versus other countries, focusing on the Inflation Reduction Act and its impact on Medicare's negotiation powers. It examines political challenges and the agreements made with pharmaceutical companies, highlighting the potential savings for Medicare recipients.